Newland Pharmaceutical Co., Ltd. (SHE:301277)
China flag China · Delayed Price · Currency is CNY
10.10
-0.20 (-1.94%)
Sep 9, 2026, 4:00 PM EDT

Newland Pharmaceutical Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Income
103.3121.25173.63158.98132.3114.98
Depreciation & Amortization
62.9655.0737.8431.0824.2420.86
Other Amortization
2.082.472.231.540.16-
Loss (Gain) From Sale of Assets
-0.7---0.070.440.21
Asset Writedown & Restructuring Costs
12.771.492.621.460.320.11
Loss (Gain) From Sale of Investments
-9.66-10.44-13.95-17.6-1.52-0.17
Provision & Write-off of Bad Debts
1.2-0.872.27-3.62.2311.14
Other Operating Activities
5.498.635.05-0.656.296.54
Change in Accounts Receivable
23.5366.03-82.3117.51-146.8-99.16
Change in Inventory
-25.8-32.92-18.2521.625.05-29.15
Change in Accounts Payable
-86.98-93.417.32-54.728.4520
Change in Other Net Operating Assets
4.22-1.60.3-0.485.283.9
Operating Cash Flow
90.69116.94126.76259.4682.8549.08
Operating Cash Flow Growth
-4.05%-7.75%-51.14%213.19%68.80%2.55%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Capital Expenditures
-49.57-101.38-110.79-96.51-74.34-25.4
Sale of Property, Plant & Equipment
0.070.060.140.540.040.06
Investment in Securities
93.75-13.9578.28129.46-691.5-8.5
Other Investing Activities
-0.88---0.330
Investing Cash Flow
43.37-115.28-32.3633.48-765.47-33.83

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Long-Term Debt Issued
----89.09118.46
Total Debt Issued
----89.09118.46
Long-Term Debt Repaid
--1.8-3.25-2.75-203.05-100
Lease Payments
-1.8-1.8-3.25-2.75-2.9-
Total Debt Repaid
-0.94-1.8-3.25-2.75-203.05-100
Net Debt Issued (Repaid)
-0.94-1.8-3.25-2.75-113.9618.46
Issuance of Common Stock
----838.574
Common Dividends Paid
-78.42-112.02-80.02-66.68-6.77-36.7
Other Financing Activities
1.08----19.09-6.94
Financing Cash Flow
-78.28-113.82-83.26-69.43698.74-21.19

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Net Cash Flow
55.78-112.1611.14223.5116.12-5.94

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Free Cash Flow
41.1215.5515.97162.948.523.68
Free Cash Flow Growth
--2.63%-90.20%1816.39%-64.10%-23.36%
Free Cash Flow Margin
5.79%2.31%2.20%25.01%1.35%4.61%
Free Cash Flow Per Share
0.100.040.040.420.030.08
Levered Free Cash Flow
15.1822.3329.72158.98-11.33-12.63
Unlevered Free Cash Flow
15.2322.4629.78159.06-7.03-8.43
Free Cash Flow After Leases
39.3213.7512.73160.195.6123.68

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Jan '23 Jan '22
Cash Income Tax Paid
37.2438.5853.7243.5966.6843.77
Change in Working Capital
-86.74-60.64-82.9388.32-81.62-104.59